Braze Inc vs Enveric Biosciences Inc — how do they compare? Braze Inc trades at $26.15 (market cap $2.99B), while Enveric Biosciences Inc trades at $1.25 (market cap $5.36M). The key difference: Braze Inc is far larger — about 557.8× Enveric Biosciences Inc's market cap, and Braze Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| BRZE | ENVB | |
|---|---|---|
Market Cap | $2.99B | $5.36M |
Sector | Technology | Health |
52-Week High | $36.19 | $17.40 |
52-Week Low | $15.79 | $1.28 |
Enterprise Value | $2.69B | $449.11K |
Signals from Pluang's Aura AI — not financial advice
Braze (BRZE) trades at $26.60, up 5.85% with strong bullish momentum. The stock shows robust revenue growth, increasing from $238M in 2022 to $593M in 2025, though profitability remains negative with a -15.51% net margin. Technical indicators show bullish moving averages but overbought RSI levels. Recent news highlights Goldman Sachs initiation and strong Q1 2027 results with accelerating revenue growth and AI-driven customer engagement tools.
Outlook remains positive with 96% analyst buy ratings and $34.78 consensus target, representing 31% upside. Key risks include persistent losses despite revenue growth and competitive pressures in customer engagement software. The company's AI capabilities and fourth straight quarter of organic revenue acceleration provide growth catalysts, but investors should monitor profitability improvements.
No Aura AI signal available yet.
Trailing returns across standard periods
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →